Renalytix PLC Total Voting Rights
31 May 2024 - 1:30AM
RNS Regulatory News
RNS Number : 5265Q
Renalytix PLC
30 May 2024
Renalytix
plc
("Renalytix" or the
"Company")
Total Voting
Rights
LONDON and SALT LAKE CITY - 30
May 2024 -
Renalytix
plc (NASDAQ: RNLX) (LSE: RENX)
announces that at today's date, the Company's
total issued share capital is 154,368,191
Ordinary Shares of £0.0025 each in the capital of the
Company ("Ordinary Shares"). Each Ordinary Share carries the right
to one vote at a general meeting of the Company.
The Company does not hold any Ordinary Shares in
treasury.
The above figure may be used by
shareholders in the Company as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change in their interest in, the share capital of
the Company under the Financial Conduct Authority's Disclosure
Guidance and Transparency Rules.
For further information,
please contact:
Renalytix plc
|
www.renalytix.com
|
James McCullough, CEO
|
Via Walbrook
PR
|
|
|
Stifel (Nominated Adviser, Joint Broker)
|
Tel: 020 7710
7600
|
Alex Price / Nicholas Moore / Nick
Harland / Samira Essebiyea
|
|
Harry Billen
|
|
Investec Bank plc (Joint Broker)
|
Tel: 020 7597
4000
|
Gary Clarence / Shalin
Bhamra
|
|
|
|
Walbrook PR Limited
Paul McManus / Alice Woodings /
Charlotte Edgar
|
Tel: 020 7933 8780 or
renalytix@walbrookpr.com
Mob: 07980 541 893 / 07407 804 654 /
07884 664 686
|
|
|
CapComm Partners
|
|
Peter DeNardo
|
Tel:
415-389-6400 or investors@renalytix.com
|
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX)
is an in-vitro diagnostics and laboratory services company that is
the global founder and leader in the new field of bioprognosis™ for
kidney health. The leadership team, with a combined 200+ years of
healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment
for rapid progressive decline in kidney function in adult patients
with T2D and early CKD (stages 1-3). We believe that by
understanding how disease will progress, patients and providers can
take action early to improve outcomes and reduce overall health
system costs. For more information, visit
www.renalytix.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
TVRQKKBBPBKDOPN
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2024 to Jun 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From Jun 2023 to Jun 2024